ÂÜÀòÂÒÂ×

Mike Rothe has a strong background in the life sciences industry, with experience in various leadership roles. Mike served as the CEO of IBA Lifesciences, where they focused on developing innovative products and technologies for life science applications. Prior to that, they were the CEO of ImmunoQure AG and ImmunoQure Research AG, where they held the position of CEO and Delegate of the Board of Directors. Mike also served as the CEO of Igenica, Inc. In addition, Mike Rothe was the Managing Director, CSO, and Co-Founder of U3 Pharma AG, where they worked on discovering novel targets and developing antibody therapeutics for cancer. Mike held the position of VP R&D & CSO at Develogen AG, where they focused on discovering novel targets and developing small molecule therapeutics for metabolic disorders. Mike also worked as a Staff Scientist at Tularik, focusing on the discovery of novel targets and development of small molecule therapeutics for inflammatory diseases. Mike Rothe started their career as a visiting scientist at Genentech.

Mike Rothe pursued their education in the field of biochemistry and molecular biology. Mike began their academic journey at the University of Tübingen, where they obtained a Master of Science (MSc) degree in Biochemistry in 1989. Afterward, they joined the Max Planck Institute for Developmental Biology in Tübingen for one year. Following this, they went on to complete their Doctor of Philosophy (PhD) degree in Molecular Biology at Ludwig-Maximilians-Universität München, finishing in 1992. During this time, they also spent a year at the Max Planck Institute for Biophysical Chemistry in Göttingen, although the specific degree or field of study for this period is not provided.